Evidence map›Paper›PMID 29288367›Full record

ArticleIntensive care medicine2018

Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.

Jan J De Waele, Murat Akova, Massimo Antonelli, Rafael Canton, Jean Carlet, Daniel De Backer, George Dimopoulos, José Garnacho-Montero, Jozef Kesecioglu, Jeffrey Lipman and 8 more

Registry-linked trialAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04304456 (Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04304456 unknown statusnot on this mapstarted 2020, after this paper: background citation

Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey

TypeobservationalSponsorSCARE (Study group for carbapenem resistance)Ran2020 to 2022Enrolled810ConditionsBacteremia, Sepsis, Hospital Acquired ConditionArmsTreatment
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  5. Article
  6. Article
  7. Observational
  8. A One Health Perspective onMicroorganisms · 2026
    Review
  9. Article
  10. An explainable machine learning approach to predicting carbapenem resistance inFrontiers in cellular and infection microbiology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Pathogens (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Article
  19. Unpacking the sepsis controversy.Trauma surgery & acute care open · 2025
    Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 16 institutions in 11 countries.

Jan J De WaeleDepartment of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium. jan.dewaele@ugent.be.ORCID http://orcid.org/0000-0003-1017-9748
Murat AkovaDepartment of Infectious Diseases, Hacettepe University School of Medicine, 06100, Ankara, Turkey.
Massimo AntonelliDepartment of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.
Rafael CantonServicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Jean CarletWorld Alliance Against Antibiotic Resistance (WAAAR), Creteil, France.
Daniel De BackerDepartment of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium.
George DimopoulosDepartment of Critical Care, Medical School, University Hospital ATTIKON, National and Kapodistrian University of Athens, Athens, Greece.
José Garnacho-MonteroIntensive Care Clinical Unit, Virgen Macarena University Hospital, Seville, Spain.
Jozef KeseciogluDepartment of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Jeffrey LipmanRoyal Brisbane and Womens' Hospital, The University of Queensland, Brisbane, Australia.
Mervyn MerWits-UQ Critical Care Infection Collaboration, Johannesburg, South Africa.
José-Artur PaivaGrupo de Infecçao e Sépsis, Department of Emergency and Intensive Care, Facuilty of Medicine, Centro Hospitalar Sao Joao, University of Porto, Porto, Portugal.
Mario PoljakFaculty of Medicine, Institute of Microbiology and Immunology, University of Ljubljana, Ljubljana, Slovenia.
Jason A RobertsFaculty of Medicine and Centre for Translational Anti-infective Pharmacodynamics, The University of Queensland, Brisbane, Australia.
Jesus Rodriguez BanoUnidad Clínica de Enfermedades Infecciosas, Departamento de Medicina, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla, Universidad de Sevilla/CSIC, Seville, Spain.
Jean-François TimsitRéanimation Medicale et des Maladies Infectieuses, Université Paris Diderot/Hopital Bichat, Paris, France.
Jean-Ralph ZaharIAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France.
Matteo BassettiInfectious Diseases Clinic, Department of Medicine University of Udine, Azienda Sanitaria Universitaria Integrata, Udine, Italy.
Hospital Universitario Virgen Macarena · ESThe University of Queensland · AUCNR de la Résistance aux Antibiotiques · FRDélégation Paris 7 · FRGhent University Hospital · BEHacettepe University · TRInstituto Ramón y Cajal de Investigación Sanitaria · ESNational and Kapodistrian University of Athens · GRUniversidade do Porto · PTUniversità Cattolica del Sacro Cuore · ITUniversité Libre de Bruxelles · BEUniversité Paris Cité · FRUniversity of Ljubljana · SIUniversity of the Witwatersrand · ZAUniversity of Udine · ITUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is a clear and present danger to patients in any intensive care unit (ICU) around the world. Whereas AMR may affect any patient in the hospital, patients in the ICU are particularly at risk of acquiring AMR infections due to the intensity of the treatment, use of invasive devices, increased risk of transmission and exposure to antibiotics. AMR is present in every ICU, although prevalence is geographically different and AMR pathogens encountered are variable. Intensive care and infectious disease specialists from the European Society of Intensive Care Medicine, European Society of Microbiology and Infectious Diseases and World Alliance Against Antimicrobial Resistance, united in the ANTARCTICA (Antimicrobial Resistance in Critical Care) coalition, call for increased awareness and action among health care professionals to reduce AMR development in critically ill patients, to improve treatment of AMR infections and to coordinate scientific research in this high-risk patient population. Close collaboration with other specialties, and combining these and other interventions in antibiotic stewardship programmes should be a priority in every ICU. Considerate antibiotic use and adopting strict infection control practices to halt AMR remains a responsibility shared by all healthcare workers, from physicians to maintenance personnel, from nurses to physiotherapists, from consultants to medical students. Together, we can reduce AMR in our ICUs and continue to treat our patients effectively.

Indexed as

Antimicrobial StewardshipDrug Resistance, BacterialIntensive Care UnitsAnti-Bacterial AgentsDrug Resistance, MultipleHumansAnti-Bacterial AgentsAntibioticInfectionResistanceStewardship

Identifiers

PMID29288367
OpenAlexW2779985585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.